A modified polypeptide and its application in the preparation of anti-inflammatory and bactericidal drugs

By designing peptide modifiers from G protein-coupled receptors and modifying the N-terminus with fatty acids, the problem of severe infection caused by drug-resistant strains was solved, significantly improving the survival rate of septic mice and reducing bacterial load, providing a new anti-infective drug solution.

CN117024564BActive Publication Date: 2026-11-17THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV COLLEGE OF MEDICINE
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310942038.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-11-17
Publication Date
2026-11-17
Estimated Expiration
2041-11-17

AI Technical Summary

Technical Problem

The emergence of drug-resistant strains such as extended-spectrum β-lactamase-producing Escherichia coli, carbapenem-resistant Klebsiella pneumoniae, and Pseudomonas aeruginosa in clinical practice has made the treatment of severe infections difficult. The current bottlenecks in antibiotic development have not been effectively resolved, and there is an urgent need for new anti-infective immunomodulatory drugs.

Method used

Starting from G protein-coupled receptors, the peptide RH-000 was designed and modified to obtain the modified peptides RH-001, RH-002, RH-003 and RH-004. Fatty acids were modified at the N-terminus to improve their permeability and stability, which can be used to prepare anti-inflammatory and bactericidal drugs.

Benefits of technology

The peptide-modified mice significantly improved the survival rate of septic mice, reduced bacterial load, and were non-cytotoxic. In particular, RH-003 and RH-004 achieved 100% survival within 72 hours, providing an effective solution for antibacterial infection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117024564B_ABST
    Figure CN117024564B_ABST
Patent Text Reader

Abstract

This invention discloses a modified polypeptide and its application in the preparation of anti-inflammatory and antibacterial drugs. The amino acid sequence of the polypeptide is shown below: Gly 1 -Val 2 -Lys 3 -Leu 4 -Tyr 5 -Gly 6 -Ser 7 -Asp 8 -Lys 9 -Ser 10 Experiments revealed that the aforementioned modified peptide was essentially non-cytotoxic and effectively reduced the bacterial load in the blood and organs of septic mice, significantly improving their survival rate. This indicates that the modified peptide can be used to treat diseases caused by bacterial infections, providing a new solution to the current problem of antibiotic resistance.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention is a divisional application of Chinese invention patent application No. 202111359409.9, filed on November 17, 2021. Technical Field

[0002] This invention belongs to the field of biomedical technology, specifically relating to a modified polypeptide and its application in the preparation of anti-inflammatory and antibacterial drugs. Background Technology

[0003] Currently, the emergence of drug-resistant bacteria such as extended-spectrum β-lactamase-producing Escherichia coli, carbapenem-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii has rendered the treatment of severe infections ineffective and greatly increased patient mortality. Antibiotic resistance has become a major medical problem that urgently needs to be solved for human health.

[0004] Currently, the main approaches to addressing antibiotic resistance in clinical practice are: (1) developing novel antibiotics; and (2) developing anti-infective immunomodulatory drugs. Since the development of novel antibiotics is currently at a bottleneck and has not achieved significant breakthroughs, anti-infective immunomodulatory drugs have become the mainstream of research and development.

[0005] G protein-coupled receptors (GPCRs) are a class of membrane protein receptors with seven transmembrane helices. They participate in most life activities in organisms, and therefore each GPCR has the potential to become a therapeutic target. Currently, about 20% of marketed drugs are GPCR-related. GPCRs are abundantly expressed on the cell membranes of various organisms and play an important role in a variety of pathophysiological processes, especially in the regulation of immunity against infection.

[0006] Developing anti-infective immunomodulatory drugs based on G protein-coupled receptors can provide new ideas for clinical anti-infective immunomodulatory therapy. Summary of the Invention

[0007] The purpose of this invention is to provide a modified polypeptide and its application in the preparation of anti-inflammatory and antibacterial drugs.

[0008] To achieve the above-mentioned objectives, the technical solution of the present invention is as follows:

[0009] A polypeptide having the amino acid sequence shown in SEQ ID No. 1.

[0010] This invention identified and obtained the above-mentioned polypeptide (named RH-000) from the full-length structure of the G protein-coupled receptor, and its amino acid sequence is as follows:

[0011] Ile 1 -Glu 2 -Arg 3 -His4 -Val 5 -Ala 6 -Ile 7 -Ala 8 -Lys 9 -Val 10 -Lys 11 -Leu 12 -Tyr 13 -Gly 14 -Ser 15 -Asp 16 -Lys 17 -Ser 18 -Cys 19 -Arg 20 ;

[0012] The study found that the peptide could significantly improve the survival rate of septic mice, with a 72-hour survival rate of over 50%, indicating that the peptide could be used to treat diseases caused by bacterial infections and providing a new solution to the current problem of antibiotic resistance.

[0013] Therefore, the present invention also provides the application of the above-mentioned polypeptide in the preparation of anti-inflammatory and bactericidal drugs.

[0014] This invention analyzes the functional regions of the aforementioned peptides through protein design and molecular dynamics simulations, and modifies the structure of the aforementioned peptides based on their functional epitopes, thereby obtaining a series of modified peptides.

[0015] Therefore, the present invention also provides a polypeptide modified body, which is obtained by the above-mentioned polypeptide modification.

[0016] The aforementioned modified polypeptide has the following amino acid sequence:

[0017] Gly 1 -Val 2 -Lys 3 -Leu 4 -Tyr 5 -Gly 6 -Ser 7 -Asp 8 -Lys 9 -Ser 10 It was named RH-001;

[0018] Or, Gly 1 -Val 2 -Lys 3 -Leu 4 -Tyr 5 It was named RH-002;

[0019] Or, Gly 1 -Val 2 -Ala 3 -Ile 4 -Ala 5 -Lys 6 -Val 7 -Lys 8 -Leu 9 -Tyr 10 It was named RH-003;

[0020] Or, Gly 1 -Ile 2 -Glu 3 -Arg 4 -His 5 -Val 6 -Ala 7 -Ile 8 -Ala 9 -Lys 10 -Val 11 It was named RH-004.

[0021] Experiments revealed that the aforementioned modified peptides exhibited minimal cytotoxicity and effectively reduced bacterial load in the blood and organs of septic mice, significantly improving their survival rate. Specifically, the 72-hour survival rates of septic mice treated with RH-001 and RH-002 were 89% and 67%, respectively, significantly superior to the 56% survival rate of the RH-000 treatment group. RH-003 further enhanced the 72-hour survival rate of septic mice to 100%, demonstrating even more significant antibacterial infection resistance.

[0022] Preferably, in the aforementioned modified peptide, the free amino group of the N-terminal amino acid is linked to a fatty acid via a dehydration condensation reaction. Adding a fatty acid group to the N-terminus enhances both the permeability and stability of the peptide, thereby facilitating its intended efficacy.

[0023] As a further optimization, the free amino group at the N-terminal Gly of the peptide modifier RH-004 is linked to a fatty acid via a dehydration condensation reaction. Treatment of septic mice with the peptide modifier RH-M-004 obtained through this further modification resulted in a 100% 72-hour survival rate for the septic mice.

[0024] Preferably, in the above-mentioned modified polypeptide, the fatty acid is myristic acid, lauric acid, or palmitic acid.

[0025] Based on the excellent properties of the above-mentioned modified peptides, the present invention also provides the application of the above-mentioned modified peptides in the preparation of anti-inflammatory and bactericidal drugs.

[0026] Compared with the prior art, the beneficial effects of the present invention are reflected in:

[0027] (1) The present invention identified and obtained the polypeptide RH-000 from the full-length structure of G protein-coupled receptor. The study found that the polypeptide can significantly improve the survival rate of septic mice. The 72-hour survival rate of septic mice reached more than 50%, indicating that the polypeptide can be used to treat diseases caused by bacterial infection, providing a new solution to the current problem of antibiotic resistance.

[0028] (2) This invention analyzes the action regions of the above-mentioned peptides through protein design and molecular dynamics simulation, and modifies the structure of the above-mentioned peptides based on the action epitopes to obtain a series of peptide modifiers RH-001, RH-002, RH-003 and RH-004. The experiment found that the above-mentioned peptide modifiers are basically non-cytotoxic and can effectively reduce the bacterial load in the blood and organs of septic mice and significantly improve the survival rate of septic mice. Among them, the 72h survival rates of septic mice in the RH-001 and RH-002 treatment groups were 89% and 67%, respectively, which were significantly better than the 72h survival rate of septic mice in the RH-000 treatment group of 56%. RH-003 can increase the 72h survival rate of septic mice to 100%, and its antibacterial infection performance is more significant and has greater application potential.

[0029] (3) In this invention, fatty acids are attached to the free amino groups of the N-terminal amino acids of each polypeptide modifier through a dehydration condensation reaction. Studies have shown that after attaching fatty acids, the polypeptide modifier RH-004 can increase the 72-hour survival rate of septic mice to 100%, and its antibacterial infection performance is further optimized, with greater application potential. Attached Figure Description

[0030] Figure 1 The HPLC purification results of the polypeptide RH-000 of the present invention are shown in the figure.

[0031] Wherein, Pump A: 0.065% trifluoroacetic in 100% water (v / v) indicates mobile phase A: a 0.065% trifluoroacetic acid aqueous solution; Pump B: 0.05% trifluoroacetic in 100% acetonitrile (v / v) indicates mobile phase B: a 0.05% trifluoroacetic acid acetonitrile solution; Total Flow: 1 ml / min indicates flow rate: 1 ml / min; Wavelength: 220 nm indicates wavelength: 220 nm; Time indicates gradient elution time; Module indicates elution program; Command indicates elution instruction; Value indicates elution volume; ColumnPerformance indicates column performance; Detector A indicates detector A; Column: Inertsil OD-3 4.6 x 250 mm indicates column: (model) Inertsil OD-3, (specification) 4.6 x 250mm; Chromatogram indicates the chromatogram; mV indicates the response intensity; min indicates (retention time) / minute; Detector A Channel 1 220 nm indicates that the detection wavelength of detector A is 220nm; Peak Table indicates the peak table, Peak indicates the peak, Ret. Time indicates the retention time, Area indicates the peak area, Height indicates the peak height, and Total indicates the total; the same applies below;

[0032] Figure 2 This is a mass spectrometry identification result of the polypeptide RH-000 of the present invention;

[0033] Wherein, Mass Spectrum represents mass spectrometry; Positve Intensity represents positive intensity; m / z represents mass-to-charge ratio, and the same applies below;

[0034] Figure 3 This is a diagram showing the MASS identification results of the polypeptide RH-001 of the present invention;

[0035] Figure 4 The image shows the HPLC purification results of the polypeptide RH-001 of this invention.

[0036] Wherein, LC Time Program indicates a gradient elution program for liquid chromatography; Equipment: ZJ20010140 indicates the equipment (model): ZJ20010140; the same applies below.

[0037] Figure 5 The HPLC purification results of the polypeptide RH-002 of this invention are shown in the figure.

[0038] Figure 6 This is a infographic showing the MASS identification results of the polypeptide RH-002 of the present invention;

[0039] Figure 7 This is a diagram showing the MASS identification results of the polypeptide RH-003 of the present invention;

[0040] Figure 8 The HPLC purification results of the polypeptide RH-003 of the present invention are shown in the figure.

[0041] Figure 9 The HPLC purification results of the polypeptide RH-004 of the present invention are shown in the figure.

[0042] Figure 10 This is a diagram showing the MASS identification results of the polypeptide RH-004 of the present invention;

[0043] Figure 11 This is a diagram showing the MASS identification results of the polypeptide RH-M-001 of the present invention;

[0044] Figure 12 The HPLC purification results of the polypeptide RH-M-001 of this invention are shown in the figure.

[0045] Figure 13 This is a chromatogram showing the HPLC purification results of the polypeptide RH-M-002 of the present invention;

[0046] Figure 14 This is a diagram showing the MASS identification results of the polypeptide RH-M-002 of the present invention;

[0047] Figure 15 This is a diagram showing the MASS identification results of the polypeptide RH-M-003 of the present invention;

[0048] Figure 16 The HPLC purification results of the polypeptide RH-M-003 of the present invention are shown in the figure.

[0049] Figure 17 This is a chromatogram showing the HPLC purification results of the polypeptide RH-M-004 of the present invention;

[0050] Figure 18 This is a diagram showing the MASS identification results of the polypeptide RH-M-004 of the present invention;

[0051] Figure 19 The results of the CCK8 cytotoxicity assay for the polypeptide modified product RH-001 of this invention;

[0052] Figure 20 The results of the CCK8 cytotoxicity assay for the polypeptide modified form RH-002 of this invention;

[0053] Figure 21 The results of the CCK8 cytotoxicity assay of the polypeptide modified RH-003 of the present invention;

[0054] Figure 22 The results of the CCK8 cytotoxicity assay for the polypeptide modified product RH-004 of this invention;

[0055] Figure 23 The results of the CCK8 cytotoxicity assay for the polypeptide modified product RH-M-001 of this invention;

[0056] Figure 24 The results of the CCK8 cytotoxicity assay for the polypeptide modified product RH-M-002 of this invention;

[0057] Figure 25 The results of the CCK8 cytotoxicity assay for the polypeptide modified product RH-M-003 of this invention;

[0058] Figure 26 The results of the CCK8 cytotoxicity assay for the polypeptide modified product RH-M-004 of this invention;

[0059] Figure 27 Kaplan-Meier survival curves of septic mice after treatment with the polypeptide RH-000 and its modified polypeptides RH-001, RH-002, RH-003 and RH-004 of the present invention.

[0060] Figure 28 Kaplan-Meier survival curves of septic mice after treatment with the polypeptide RH-000 and its modified polypeptides RH-M-001, RH-M-002, RH-M-003 and RH-M-004 of the present invention.

[0061] Figure 29 The changes in bacterial load in the blood of septic mice after treatment with peptide modifiers RH-001, RH-002, RH-003 and RH-M-004;

[0062] Figure 30 The changes in bacterial load in the liver of septic mice after treatment with the polypeptide modifiers RH-001, RH-002, RH-003 and RH-M-004;

[0063] Figure 31 The changes in bacterial load in the spleen of septic mice after treatment with peptide modifiers RH-001, RH-002, RH-003 and RH-M-004;

[0064] Figure 32The changes in bacterial load in the lungs of septic mice after treatment with the polypeptide modifiers RH-001, RH-002, RH-003 and RH-M-004;

[0065] Figure 33 The changes in bacterial load in the kidneys of septic mice after treatment with the polypeptide modifiers RH-001, RH-002, RH-003 and RH-M-004. Detailed Implementation

[0066] The technical solution of the present invention will be further described in detail below with reference to the accompanying drawings and specific embodiments.

[0067] Example 1

[0068] In this embodiment, the polypeptide RH-000 was identified and obtained from the full-length structure of the G protein-coupled receptor. The amino acid sequence of the polypeptide RH-000 is shown in SEQ ID No. 1:

[0069] Ile 1 -Glu 2 -Arg 3 -His 4 -Val 5 -Ala 6 -Ile 7 -Ala 8 -Lys 9 -Val 10 -Lys 11 -Leu 12 -Tyr 13 -Gly 14 -Ser 15 -Asp 16 -Lys 17 -Ser 18 -Cys 19 -Arg 20 ;

[0070] The synthesis method of the polypeptide RH-000 includes the following steps:

[0071] (1) Resin swelling: Place 2-Chlorotrityl Chloride Resin resin into a reaction tube, add DMF (15 ml / g), and shake for 30 min;

[0072] (2) Coupling the first amino acid: The solvent was removed by filtration through the sand core, and an equimolar amount of Fmoc-Arg(pbf)-OH amino acid was taken. Then, 10 times the molar excess of DIEA and 3 times the excess of HBTU were added. Finally, DMF was added to dissolve the amino acid and shaken for 30 min.

[0073] (3) Deprotection: Remove DMF, add 20% piperidine DMF solution (15ml / g), 5min, remove again and add 20% piperidine DMF solution (15ml / g), 15min;

[0074] (4) Detection: Remove the piperidine solution, take a dozen resin grains, wash them three times with ethanol, add one drop each of ninhydrin, KCN and phenol solution, heat at 105℃-110℃ for 5 minutes, and the reaction is positive when it turns dark blue;

[0075] (5) Washing: DMF (10ml / g) twice, methanol (10ml / g) twice, DMF (10ml / g) twice;

[0076] (6) Condensation: Protective amino acid (Fmoc-Cys(tBu)-OH) in three times excess, HBTU in three times excess, both dissolved in as little DMF as possible, added to the reaction tube, and immediately added in ten times excess NMM. React for 30 min;

[0077] (7) Washing: DMF (10ml / g) once, methanol (10ml / g) twice, DMF (10ml / g) twice;

[0078] (8) Repeat steps (2) to (6) to connect the amino acids in the sequence from right to left;

[0079] (9) Cut the protecting groups of the polypeptide side chain, and then precipitate the polypeptide with cold diethyl ether;

[0080] Preparation of cutting fluid (10 g): TFA 94.5%; Water 2.5%; EDT 2.5%; TIS 1%;

[0081] Cutting time: 120 min;

[0082] (10) The polypeptide product precipitated by diethyl ether was dried and then identified, and purified by HPLC (e.g. Figure 1 ) and Mass identification (such as Figure 2 The polypeptide RH-000 of this embodiment was obtained.

[0083] Example 2

[0084] In this embodiment, the structure of polypeptide RH-000 was further modified to obtain a series of polypeptide modifiers. The amino acid sequences of each polypeptide modifier are shown in Table 1.

[0085] Table 1. Peptide-modified bodies and their amino acid sequences

[0086] serial number amino acid sequence N-terminal modification RH-001 <![CDATA[Gly 1 -Val 2 -Light 3 -Leu 4 -Bull 5 -Gly 6 -See 7 -Aspen 8 -Light 9 -See 10 (GVKLYGSDKS,SEQ ID No.2)]]> none RH-002 <![CDATA[Gly 1 -Val 2 -Lys 3 -Leu 4 -Taurus 5 (GVKLY,SEQ ID No.3)]]> none RH-003 <![CDATA[Gly 1 -Val 2 -God 3 -Ile 4 -God 5 -Lys 6 -Val 7 -Lys 8 -Leu 9 -Taurus 10 (GVAIAKVKLY,SEQ ID No.4)]]> none RH-004 <![CDATA[Gly 1 -Ile 2 -Glu 3 -Arg 4 -His 5 -Val 6 -Ala 7 -Ile 8 -Ala 9 -Lys 10 -Val 11 (GIERHVAIAKV,SEQ ID No.5)]]> none RH-M-001 <![CDATA[Gly 1 -Val 2 -Light 3 -Leu 4 -Bull 5 -Gly 6 -See 7 -Aspen 8 -Light 9 -See 10 (GVKLYGSDKS,SEQ ID No.2)]]> Myristoyl- RH-M-002 <![CDATA[Gly 1 -Val 2 -Lys 3 -Leu 4 -Taurus 5 (GVKLY,SEQ ID No.3)]]> Myristoyl- RH-M-003 <![CDATA[Gly 1 -Val 2 -God 3 -Ile 4 -God 5 -Lys 6 -Val 7 -Lys 8 -Leu 9 -Taurus 10 (GVAIAKVKLY,SEQ ID No.4)]]> Myristoyl- RH-M-004 <![CDATA[Gly 1 -Ile 2 -Glu 3 -Arg 4 -His 5 -Val 6 -Ala 7 -Ile 8 -Ala 9 -Lys 10 -Val 11 (GIERHVAIAKV,SEQ ID No.5)]]> Myristoyl-

[0087] As shown in Table 1, in this embodiment, the target region of peptide RH-000 was first analyzed by protein design and molecular dynamics simulation, and the structure of peptide RH-000 was modified based on the target epitope, resulting in peptide modifiers RH-001, RH-002, RH-003 and RH-004. Then, myristic acid was modified at the N-terminus of peptide modifiers RH-001, RH-002, RH-003 and RH-004 by dehydration condensation reaction between the hydroxyl groups of fatty acids and the free amino groups on the N-terminal amino acid residues, further resulting in peptide modifiers RH-M-001, RH-M-002, RH-M-003 and RH-M-004.

[0088] The synthesis method of the polypeptide modifier RH-001 includes the following steps:

[0089] (1) Resin swelling: Place 2-Chlorotrityl Chloride Resin resin into a reaction tube, add DMF (15 ml / g), and shake for 30 min;

[0090] (2) Coupling the first amino acid: The solvent was removed by filtration through the sand core, and an equimolar amount of Fmoc-Ser-OH amino acid was taken, followed by 10 times the molar excess of DIEA and 3 times the excess of HBTU. Finally, DMF was added to dissolve the amino acid and shaken for 30 min.

[0091] (3) Deprotection: Remove DMF, add 20% piperidine DMF solution (15ml / g), 5min, remove again and add 20% piperidine DMF solution (15ml / g), 15min;

[0092] (4) Detection: Remove the piperidine solution, take a dozen resin grains, wash them three times with ethanol, add one drop each of ninhydrin, KCN and phenol solution, heat at 105℃-110℃ for 5 minutes, and the reaction is positive when it turns dark blue;

[0093] (5) Washing: DMF (10ml / g) twice, methanol (10ml / g) twice, DMF (10ml / g) twice;

[0094] (6) Condensation: Protective amino acid (Fmoc-Lys(Boc)-OH) in excess of three times, HBTU in excess of three times, both dissolved in as little DMF as possible, added to the reaction tube, and immediately added in excess of ten times NMM. React for 30 min;

[0095] (7) Washing: DMF (10ml / g) once, methanol (10ml / g) twice, DMF (10ml / g) twice;

[0096] (8) Repeat steps (2) to (6) to connect the amino acids in the sequence from right to left;

[0097] (9) Cut the protecting groups of the polypeptide side chain, and then precipitate the polypeptide with cold diethyl ether;

[0098] Preparation of cutting fluid (10 g): TFA 94.5%; Water 2.5%; EDT 2.5%; TIS 1%;

[0099] Cutting time: 120 min;

[0100] (10) The polypeptide product precipitated by diethyl ether was dried and then identified, and purified by HPLC. Figure 4 ) and Mass identification ( Figure 3 The polypeptide modified RH-001 of this embodiment was obtained.

[0101] The method for synthesizing the polypeptide modifier RH-002 includes the following steps:

[0102] (1) Resin swelling: Place 2-Chlorotrityl Chloride Resin resin into a reaction tube, add DMF (15 ml / g), and shake for 30 min;

[0103] (2) Coupling the first amino acid: The solvent was removed by filtration through the sand core, and an equimolar amount of Fmoc-Tyr(tBu)-OH amino acid was taken, followed by 10 times the molar excess of DIEA and 3 times the excess of HBTU. Finally, DMF was added to dissolve the amino acid and shaken for 30 min.

[0104] (3) Deprotection: Remove DMF, add 20% piperidine DMF solution (15ml / g), 5min, remove again and add 20% piperidine DMF solution (15ml / g), 15min;

[0105] (4) Detection: Remove the piperidine solution, take a dozen resin grains, wash them three times with ethanol, add one drop each of ninhydrin, KCN and phenol solution, heat at 105℃-110℃ for 5 minutes, and the reaction is positive when it turns dark blue;

[0106] (5) Washing: DMF (10ml / g) twice, methanol (10ml / g) twice, DMF (10ml / g) twice;

[0107] (6) Condensation: Protect the amino acid (Fmoc-Leu-OH) in excess by three times, and HBTU in excess by three times. Dissolve both in DMF as little as possible, add to the reaction tube, and immediately add NMM in excess by ten times. React for 30 min;

[0108] (7) Washing: DMF (10ml / g) once, methanol (10ml / g) twice, DMF (10ml / g) twice;

[0109] (8) Repeat steps (2) to (6) to connect the amino acids in the sequence from right to left;

[0110] (9) Cut the protecting groups of the polypeptide side chain, and then precipitate the polypeptide with cold diethyl ether;

[0111] Preparation of cutting fluid (10 g): TFA 94.5%; Water 2.5%; EDT 2.5%; TIS 1%;

[0112] Cutting time: 120 min;

[0113] (10) The polypeptide product precipitated by diethyl ether was dried and then identified, and purified by HPLC. Figure 5 ) and Mass identification ( Figure 6 ), to obtain the polypeptide modified form RH-002 of this embodiment.

[0114] The method for synthesizing the polypeptide modifier RH-003 includes the following steps:

[0115] (1) Resin swelling: Place 2-Chlorotrityl Chloride Resin resin into a reaction tube, add DMF (15 ml / g), and shake for 30 min;

[0116] (2) Coupling the first amino acid: The solvent was removed by filtration through the sand core, and an equimolar amount of Fmoc-Tyr(tBu)-OH amino acid was taken, followed by 10 times the molar excess of DIEA and 3 times the excess of HBTU. Finally, DMF was added to dissolve the amino acid and shaken for 30 min.

[0117] (3) Deprotection: Remove DMF, add 20% piperidine DMF solution (15ml / g), 5min, remove again and add 20% piperidine DMF solution (15ml / g), 15min;

[0118] (4) Detection: Remove the piperidine solution, take a dozen resin grains, wash them three times with ethanol, add one drop each of ninhydrin, KCN and phenol solution, heat at 105℃-110℃ for 5 minutes, and the reaction is positive when it turns dark blue;

[0119] (5) Washing: DMF (10ml / g) twice, methanol (10ml / g) twice, DMF (10ml / g) twice;

[0120] (6) Condensation: Protect the amino acid (Fmoc-Leu-OH) in excess by three times, and HBTU in excess by three times. Dissolve both in DMF as little as possible, add to the reaction tube, and immediately add NMM in excess by ten times. React for 30 min;

[0121] (7) Washing: DMF (10ml / g) once, methanol (10ml / g) twice, DMF (10ml / g) twice;

[0122] (8) Repeat steps (2) to (6) to connect the amino acids in the sequence from right to left;

[0123] (9) Cut the protecting groups of the polypeptide side chain, and then precipitate the polypeptide with cold diethyl ether;

[0124] Preparation of cutting fluid (10 g): TFA 94.5%; Water 2.5%; EDT 2.5%; TIS 1%;

[0125] Cutting time: 120 min;

[0126] (10) The polypeptide product precipitated by diethyl ether was dried and then identified, and purified by HPLC. Figure 8 ) and Mass identification ( Figure 7 The polypeptide modified RH-003 of this embodiment was obtained.

[0127] The method for synthesizing the polypeptide modifier RH-004 includes the following steps:

[0128] (1) Resin swelling: Place 2-Chlorotrityl Chloride Resin resin into a reaction tube, add DMF (15 ml / g), and shake for 30 min;

[0129] (2) Coupling the first amino acid: The solvent was removed by filtration through the sand core, and an equimolar amount of Fmoc-Val-OH amino acid was taken, followed by 10 times the molar excess of DIEA and 3 times the excess of HBTU. Finally, DMF was added to dissolve the amino acid and shaken for 30 min.

[0130] (3) Deprotection: Remove DMF, add 20% piperidine DMF solution (15ml / g), 5min, remove again and add 20% piperidine DMF solution (15ml / g), 15min;

[0131] (4) Detection: Remove the piperidine solution, take a dozen resin grains, wash them three times with ethanol, add one drop each of ninhydrin, KCN and phenol solution, heat at 105℃-110℃ for 5 minutes, and the reaction is positive when it turns dark blue;

[0132] (5) Washing: DMF (10ml / g) twice, methanol (10ml / g) twice, DMF (10ml / g) twice;

[0133] (6) Condensation: Protective amino acid (Fmoc-Lys(Boc)-OH) in excess of three times, HBTU in excess of three times, both dissolved in as little DMF as possible, added to the reaction tube, and immediately added in excess of ten times NMM. React for 30 min;

[0134] (7) Washing: DMF (10ml / g) once, methanol (10ml / g) twice, DMF (10ml / g) twice;

[0135] (8) Repeat steps (2) to (6) to connect the amino acids in the sequence from right to left;

[0136] (9) Cut the protecting groups of the polypeptide side chain, and then precipitate the polypeptide with cold diethyl ether;

[0137] Preparation of cutting fluid (10 g): TFA 94.5%; Water 2.5%; EDT 2.5%; TIS 1%;

[0138] Cutting time: 120 min;

[0139] (10) The polypeptide product precipitated by diethyl ether was dried and then identified, and purified by HPLC. Figure 9 ) and Mass identification ( Figure 10 ), to obtain the polypeptide modified form RH-004 of this embodiment.

[0140] The synthesis methods of the polypeptide modifiers RH-M-001, RH-M-002, RH-M-003 and RH-M-004 include the following steps:

[0141] (1) Assemble and synthesize the peptide chain according to the above synthesis steps of RH-001;

[0142] (2) After the peptide chain is assembled, add an excess of myristic acid to condense and couple it to the N-terminus of the peptide chain.

[0143] (3) Cut the protecting groups of the polypeptide side chain, and then precipitate the polypeptide with cold diethyl ether;

[0144] Preparation of cutting fluid (10 g): TFA 94.5%; Water 2.5%; EDT 2.5%; TIS 1%;

[0145] Cutting time: 120 min;

[0146] (4) The polypeptide product precipitated by diethyl ether was dried and then identified, and purified by HPLC. Figure 12 ) and Mass identification ( Figure 11 ), to obtain the polypeptide modified RH-M-001.

[0147] The modified peptide RH-M-002 was obtained using the same method as described above (HPLC purification results are shown in [reference needed]). Figure 13 Mass identification results are available in [link / reference]. Figure 14 ), RH-M-003 (HPLC purification results are shown in...) Figure 16 Mass identification results are available in [link / reference]. Figure 15 ) and RH-M-004 (HPLC purification results are shown in the figure) Figure 17 Mass identification results are available in [link / reference]. Figure 18 ).

[0148] The patentee continued to test the biosafety and bioefficacy of the aforementioned modified peptides.

[0149] First, the biosafety of each peptide-modified organism was analyzed using the CCK8 cytotoxicity assay. The test methods included:

[0150] Bone marrow-derived macrophage (BMDM) suspension was seeded into 96-well plates at 100 μl per well. Following a concentration gradient, peptide RH-000 and its modified forms were added to each well of the cell suspension at concentrations of 0 μM (control group), 3.125 μM, 6.25 μM, 12.5 μM, 25 μM, and 50 μM, respectively. After incubation for 24 hours, cell viability was measured using a microplate reader (the experiment was repeated three times). The results are shown below. Figures 19 to 26 As shown.

[0151] Depend on Figures 19 to 26 As can be seen, compared with the control group, the cell activity of each peptide-modified group did not decrease significantly with the increase of drug concentration, indicating that the peptide-modified products prepared in this invention are non-cytotoxic and have high biosafety.

[0152] The sepsis treatment efficacy of peptide RH-000 and various peptide modifiers was then tested to analyze their bioavailability. The testing method was as follows:

[0153] Take polypeptide RH-000 and various polypeptide modifiers, and set up corresponding experimental groups in sequence. Each group contains 9 mice, and each mouse is injected intraperitoneally with 8×10 6 CFU of E. coli was collected, and mice were then treated with a single dose of peptide RH-000 and each peptide modification (10 mg / kg per mouse). A control group was also included, receiving the same dose of saline. The therapeutic effects of peptide RH-000 and each peptide modification in septic mice were analyzed using Kaplan-Meier survival curves. The results are shown below. Figure 27 and Figure 28 .

[0154] like Figure 27As shown, compared with the control group, peptide RH-000 and peptide modifiers RH-001, RH-002, RH-003, and RH-004 all significantly improved the survival rate of mice. Specifically, the 72-hour survival rate of septic mice in the RH-000 treatment group was 56%, while the 72-hour survival rates of septic mice in the RH-001 and RH-002 treatment groups reached 89% and 67%, respectively, significantly better than the RH-000 treatment group. Furthermore, the survival rate of septic mice in the peptide modifier RH-003 treatment group remained consistently at 100%, significantly better than the control group and other treatment groups.

[0155] like Figure 28 As shown, compared with the control group, peptide RH-000 and peptide modifiers RH-M-001, RH-M-002, RH-M-003, and RH-M-004 significantly improved the survival rate of mice. Among them, the 72-hour survival rate of mice treated with peptide modifiers RH-M-001, RH-M-002, and peptide RH-000 was between 50% and 70%; while the survival rate of mice treated with peptide modifier RH-M-004 remained at 100% throughout, which was significantly better than the control group and other treatment groups.

[0156] Notably, after N-terminal modification with myristic acid, the 12-hour survival rate of the RH-M-003 treatment group was superior to that of the RH-003 treatment group, while the 36-hour survival rates of the RH-M-001 and RH-M-002 treatment groups were superior to those of the RH-001 and RH-002 treatment groups, respectively. In particular, the 72-hour survival rate of the RH-M-004 treatment group was significantly better than that of the RH-004 treatment group, indicating that N-terminal modification with myristic acid is beneficial for improving mouse survival. This may be because myristic acid modification improves the permeability and stability of the modified peptide, allowing it to exert its intended efficacy.

[0157] Based on the premise of balancing biosafety and bioavailability, selecting peptides with fewer amino acids and fewer modifications can improve the success rate and purity of peptide synthesis, reduce production costs, and improve the economics of preparation. Under this premise, RH-001, RH-002, RH-003, and RH-M-004 were selected as drugs for later research to test the effect of drug treatment on bacterial load in mice.

[0158] The testing method included: setting up five experimental groups and one control group, with 6 mice in each group, and injecting each mouse intraperitoneally with 8×10⁸ mg / L of water. 6 CFU of E. coli was administered to mice, followed by single-dose treatment with saline (control group), RH-001, RH-002, RH-003, and RH-M-004 (10 mg / kg per mouse). Eight hours after treatment, blood, liver, spleen, lung, and kidney samples were collected for bacterial quantification; results are as follows. Figure 29 , Figure 30 , Figure 31 , Figure 32 and Figure 33 As shown.

[0159] Depend on Figure 29 , Figure 30 , Figure 31 , Figure 32 and Figure 33 It is evident that RH-001, RH-002, RH-003, and RH-M-004 can all effectively reduce the bacterial load in blood and organs.

Claims

1. A modified polypeptide, characterized in that, The amino acid sequence is shown below: Gly 1 -Val 2 -Light 3 -Leu 4 -Bull 5 -Gly 6 -See 7 -Aspen 8 -Light 9 -See 10 。 2. A polypeptide modifier, characterized in that, The free amino group of the N-terminal amino acid of the polypeptide modified according to claim 1 is linked to myristic acid via a dehydration condensation reaction.

3. The use of the polypeptide modified body according to any one of claims 1-2 in the preparation of anti-inflammatory and bactericidal drugs, characterized in that, The anti-inflammatory and bactericidal drug mentioned is an anti-Escherichia coli infection drug.

Citation Information

Patent Citations

  • Human alpha-defensin-5 modifier and applications thereof

    CN106146643A

  • KR20190138065A